Integra Lifesciences Holdings Corp  

(Public, NASDAQ:IART)   Watch this stock  
Find more results for Stuart Gorelick
52.49
+0.95 (1.84%)
After Hours: 52.49 0.00 (0.00%)
Dec 18, 6:19PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 51.45 - 52.62
52 week 42.50 - 52.62
Open 52.00
Vol / Avg. 241,504.00/147,449.00
Mkt cap 1.70B
P/E 57.23
Div/yield     -
EPS 0.92
Shares 32.79M
Beta 0.91
Inst. own 80%
Feb 23, 2015
Q4 2014 Integra LifeSciences Holdings Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 10, 2014
Integra LifeSciences Holdings Corp at Oppenheimer Healthcare Conference
Dec 2, 2014
Integra LifeSciences Holdings Corp at Piper Jaffray Healthcare Conference
Nov 13, 2014
Integra LifeSciences Holdings Corp Investor Meeting at North American Spine Society
Nov 3, 2014
Q3 2014 Integra LifeSciences Holdings Corp Earnings Call - Webcast
Nov 3, 2014
Q3 2014 Integra LifeSciences Holdings Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 4.27% -2.03%
Operating margin 7.72% -0.44%
EBITD margin - 10.78%
Return on average assets 2.53% -1.44%
Return on average equity 5.72% -2.87%
Employees 3,300 -
CDP Score - -

Address

311 Enterprise Drive
PLAINSBORO, NJ 08536
United States - Map
+1-609-2750500 (Phone)
+1-609-2755363 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Integra LifeSciences Holdings Corporation operates in medical technology. Integra offers solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. Integra was founded on a technology platform to repair and regenerate tissue with engineered collagen devices. The Company develops product lines for applications ranging from burn and deep tissue wounds to regeneration of Dura mater in the brain and repair of nerve and tendon. The Company manufactures and sells products in five business segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. The Company�s products include regenerative medicine implants, metal implants, instruments and equipment for orthopedic surgery, neurosurgery and general surgery. The U.S. Neurosurgery segment sells a line of products for neurosurgery and neuro critical care. The U.S. Instruments segment is a surgical instrument supplier in the United States.

Officers and directors

Stuart M. Essig Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter J. Arduini President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Glenn G. Coleman Chief Financial Officer, Principal Accounting Officer, Corporate Vice President
Age: 46
Bio & Compensation  - Reuters
Padma Thiruvengadam Chief Human Resources Officer, Corporate Vice President
Age: 49
Bio & Compensation  - Reuters
Kenneth E. Burhop Ph.D. Chief Scientific Officer, Corporate Vice President
Bio & Compensation  - Reuters
Judith E. O'Grady Corporate Vice President - Global Regulatory Affairs, Corporate Compliance Officer
Age: 63
Bio & Compensation  - Reuters
John Mooradian Corporate Vice President - Global Operations and Supply Chain
Age: 58
Bio & Compensation  - Reuters
Richard D. Gorelick Corporate Vice President, General Counsel, Administration, Secretary
Age: 53
Bio & Compensation  - Reuters
Jerry E. Corbin Corporate Vice President, Corporate Controller
Age: 53
Bio & Compensation  - Reuters
Mark A. Augusti Corporate Vice President, President, Orthopedics and Tissue Technologies
Bio & Compensation  - Reuters